Lack of correlation between ERCC1 (C8092A) single nucleotide polymorphism and efficacy/toxicity of platinum based chemotherapy in Chinese patients with advanced non-small cell lung cancer

Advances in Medical Sciences

Volumn 56, Issue 1, 2011, Pages 30-38

  Kimcurran, V ^a   Zhou, C ^a   Schmid Bindert, G ^b   Shengxiang, Ren ^a   Zhou, S ^a   Zhang, L ^a   Zhang, J ^a  

^a TONGJI UNIVERSITY   (China)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

chemotherapy; DNA repair gene; Excision repair cross complementing group 1; non small cell lung cancer; Single Nucleotide Polymorphisms

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBOPLATIN; CISPLATIN; CREATININE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; HEMOGLOBIN; NAVELBINE; PACLITAXEL;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHINESE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DRUG EFFICACY; ETHNICITY; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE SEQUENCE; GENETIC ASSOCIATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; KIDNEY FUNCTION TEST; LARGE CELL CARCINOMA; LIVER FUNCTION TEST; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PLEURA EFFUSION; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SQUAMOUS CELL CARCINOMA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR GROWTH; UREA NITROGEN BLOOD LEVEL; VOMITING;

EID: 79958102953     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.2478/v10039-011-0013-3     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007 Jan- Feb;57(1):43-66 (Pubitemid 46148091)
2. Houwen L. State of the art: lung cancer in China. Ann Thorac Cardiovasc Surg. 2003 Jun;9(3):147-8
3. Parkin DM, Bray F, Ferlay J , Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005 Mar- Apr;55(2):74-108 (Pubitemid 40372904)
4. Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998 May;4(5):1087-100 (Pubitemid 28213318)
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med. 2002 Jan 10;346:92-8 (Pubitemid 34438899)
6. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR. American Society of Clinical Oncology. American Society of Clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update J Clin Oncol. 2004 Jan 15;22(2):330-53 (Pubitemid 41095099)
7. Sancar A. DNA repair in humans. Annu Rev Genet. 1995;29: 69-105 (Pubitemid 26005337)
8. Shiraishi K, Kohno T, Tanai C, Goto Y, Kuchiba A, Yamamoto S, Tsuta K, Nokihara H, Yamamoto N, Sekine I, Ohe Y, Tamura T, Yokota J, Kunitoh H. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2010 Nov 20;28(33):4945-52
9. Suk R, Gurubhagavatula S, Park S, Zhou W, Su L, Lynch TJ, Wain JC, Neuberg D, Liu G, Christiani DC. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non- small cell lung cancer patients. Clin Cancer Res. 2005 Feb 15;11(4):1534-8 (Pubitemid 40315237)
10. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer. 2001 Oct;1(1):22-33 (Pubitemid 33741878)
11. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1513-30 (Pubitemid 36020002)
12. Review. Erratum in: Cancer Epidemiol Biomarkers Prev. 2003;12(10):1119
13. Enzlin JH, Schärer OD. The active site of the DNA repair endonuclease XPF-ERCC1 forms a highly conserved nuclease motif. EMBO J. 2002 Apr 15;21(8):2045-53 (Pubitemid 34437202)
14. Bessho T, Sancar A, Thompson LH, Thelen MP. Reconstitution of human excision nuclease with recombinant XPF-ERCC1 complex. J Biol Chem. 1997 Feb 7;272(6): 3833-7 (Pubitemid 27066894)
15. de las Peñas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, Massuti B, Queralt C, Botia M, Garcia-Gomez R, Isla D, Cobo M, Santarpia M, Cecere F, Mendez P, Sanchez JJ, Rosell R Spanish Lung Cancer Group. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006 Apr 17: 4: 668-75
16. Yu JJ, Mu C, Lee KB, Okamoto A, Reed EL, Bostick- Bruton F, Mitchell KC, Reed E. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res. 1997 Sep;382(1-2):13-20 (Pubitemid 28376643)
17. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y. Polymorphism of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000 Dec;60(24):6921-6 (Pubitemid 32059164)
18. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, Mavroudis D. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer. 2009 Mar; 10(2):118-23
19. Zhou W, Liu G, Park S, Wang Z, Wain JC, Lynch TJ, Su L, Christiani DC. Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer. Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2): 491-6 (Pubitemid 40270116)
20. Park SY, Hong YC, Kim JH, Kwak SM, Cho JH, Lee HL, Ryu JS. Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. Med Oncol. 2006; 23(4):489-98
21. Vogel U, Dybdahl M, Frentz G, Nexo BA. DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat Res. 2000 Nov 9;461(3):197-210
22. Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, Yun J, Sones E, Mallik N, Lenz HJ. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol. 2003 Mar;1(3):162-6
23. Chen P, Wiencke J, Aldape K, Kesler-Diaz A, Miike R, Kelsey K, Lee M, Liu J, Wrensch M. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev. 2000 Aug;9(8):843-7 (Pubitemid 30660059)
24. Sturgis EM, Dahlstrom KR, Spitz MR, Wei Q. DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2002 Sep;128(9):1084-8 (Pubitemid 35014604)
25. Takenaka T, Yano T, Kiyohara C, Miura N, Kouso H, Ohba T, Kometani T, Shoji F, Yoshino I, Maehara Y. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer. 2010 Jan;67(1):101-7
26. Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC, Ducreux M, Sarasin A, Praz F. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res. 2005 Sep 1;11(17):6212-7 (Pubitemid 41262950)
27. Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol. 2007 Nov 20;25(33):5172-9 (Pubitemid 350232247)
28. Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, Lopez-Vivanco G, Camps C, Botia M, Nuñez L, Sanchez-Ronco M, Sanchez JJ, Lopez-Brea M, Barneto I, Paredes A, Medina B, Artal A, Lianes P. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol. 2004 Aug;15(8):1194-203 (Pubitemid 39199306)
29. Park JY, Lee SY, Jeon HS, Bae NC, Chae SC, Joo S, Kim CH, Park JH, Kam S, Kim IS, Jung TH. Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev. 2002 Jan;11(1):23-7 (Pubitemid 34118309)
30. Okuda K, Sasaki H, Hikosaka Y, Kawano O, Yukiue H, Yano M, Fujii Y. Excision Repair Cross Complementation Group 1 Polymorphisms Predict Overall Survival after Platinum-Based Chemotherapy for Completely Resected Non- Small-Cell Lung Cancer. J Surg Res. 2009 Sep 26
31. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep;361(10):947-57